Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS Branded Medicines Tranche Framework for London and South of England

NHS England

This public procurement record has 1 release in its history.

Award

20 Aug 2024 at 15:46

Award Notice
Summary of the contracting process

NHS England has concluded the award phase of a procurement process for the NHS Branded Medicines Tranche Framework, covering London and the South of England. This framework contract, valued at approximately £380.95 million, will commence on 1st September 2024 and spans multiple regions including London, the East Midlands, East of England, North East, North West, South East, South West, West Midlands, and Yorkshire and the Humber. The framework encompasses a variety of pharmaceutical products under the CPV classification 33600000 and was procured using an open procedure. Key suppliers involved in this award include Sun Pharma UK Ltd, Biogen, Merck Sharpe & Dohme (UK) Limited, and AstraZeneca, among others, with the framework running until 31st August 2026, having options for extension up to 24 months.

This procurement presents a significant opportunity for businesses in the pharmaceutical sector to collaborate with NHS England, potentially expanding their market reach and driving growth. The framework is suitable for Small and Medium-sized Enterprises (SMEs), offering them a substantial platform to supply branded medicines across a broad geographical and institutional scope. Businesses specializing in pharmaceutical manufacturing, distribution, and supply chain logistics will find this tender particularly lucrative, enabling them to secure long-term partnerships and establish a strong presence in the healthcare market within multiple UK regions.

How relevant is this notice?

Notice Information

Notice Title

NHS Branded Medicines Tranche Framework for London and South of England

Notice Description

NHS Branded Medicines Tranche Framework for London and South of England - 1 September 2024 Offer reference number: CM/PHR/22/5689 CM/PHR/22/5689/01 - NHS Framework for Branded Medicines - London & South of England Tranche A. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/02 - NHS Framework for Branded Medicines - London & South of England Tranche B. Period of framework: 1 September 2024 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5689/03 - NHS Framework for the supply of Omalizumab and Diroximel Fumarate for the Midlands & East and North of England. Period of framework: 1 September 2024 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-b5fd17-093f7927-fa77-4248-beb7-0c8a9707d58c
Publication Source
Contracts Finder
Latest Notice
https://www.contractsfinder.service.gov.uk/Notice/5804a973-6494-40b3-8ef1-7809f1927694
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure (above threshold)
Tender Suitability
SME
Awardee Scale
Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£380,950,720 £100M-£1B
Lots Value
Not specified
Awards Value
£380,950,720 £100M-£1B
Contracts Value
Not specified

Notice Dates

Publication Date
20 Aug 20242 years ago
Submission Deadline
5 Apr 2024Expired
Future Notice Date
Not specified
Award Date
22 Jul 20242 years ago
Contract Period
1 Sep 2024 - 31 Aug 2026 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Not Specified
Awards Status
Active
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
NHS England
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England
Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
TLC North East (England), TLD North West (England), TLE Yorkshire and The Humber, TLF East Midlands (England), TLG West Midlands (England), TLI London, TLJ South East (England), TLK South West (England)
Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
29
Supplier Names

Ranbaxy (UK) Ltd

Biogen Idec Limited

Merck Sharpe & Dohme (UK) Limited

Celltrion Healthcare

ASTRAZENECA UK LIMITED

Janssen-Cilag Ltd

Organon Pharmaceuticals UK Ltd

THORNTON & ROSS LIMITED

GlaxoSmithKline UK Limited

Takeda UK Limited

Pfizer Ltd

Novartis Pharmaceuticals UK Limited

Zentiva Pharma UK Ltd

Roche Products Ltd

Eli Lilly & Company Ltd

AVENTIS PHARMA LIMITED t-a Sanofi

Accord-UK Ltd

Orifarm UK Ltd

Galapagos Biotech Ltd

Manx Healthcare Ltd

Chugai Pharma UK Ltd

Napp Pharmaceuticals Ltd

Dr.Reddy's Laboratories (UK) Limited

LEO Pharma

Gedeon Richter UK Ltd

Biosimilar Collaborations Ireland Limited

Swedish Orphan Biovitrum Ltd

Teva UK Limited

UCB Pharma Ltd

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...